0.25 CME Credits. In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.
0.25 CME Credits. Highlights from this month include Lumateperone, Lavender, treatment resistant smoking, and Clonidine patches and Tourettes. A new meta analysis published in Psychiatry Research sheds light on a critical question.
0.50 CME Credits. Learn how to address depression in older adults, identify the risk factors and triggers, distinguish depression from normal aging, and explore effective treatment options.
0.25 CME Credits. Psychiatric news covered in this episode: TMS for Teens, Olanzapine Serum Levels, Old Medication Pairing Emerges for Novel Alcoholism Treatment, Old Medication Pairing Emerges for Novel Alcoholism Treatment, Promising Option For Transitioning Insomnia Medications, Lithium's Anti-Suicide Effects in Question, Role of Omega-3 Supplements in Psychosis Risk Reduction, Caffeine and Anxiety: A Concerning Connection for Coffee Lovers.
0.25 CME Credits. Psychiatric news covered in this episode: FDA Grants Priority Review for MDMA Therapy, Benzodiazepine Withdrawal Perils, Lithium: Good for Bones?, Iloperidone Added to Anti-Psychotics with Mania Efficacy, Transdiagnostic Sleep and Circadian Treatment, A Door Closes for Clozapine-Resistant Schizophrenia, Therapy for Multi-Trauma PTSD.
In this video, we take an in-depth look at the recently FDA-approved antipsychotic, KarXT, also known by its brand name Cobenfy. This new drug represents a major breakthrough in schizophrenia treatment because, unlike traditional antipsychotics, it doesn’t rely on blocking dopamine receptors. Instead, KarXT works through a muscarinic agonist mechanism, making it a completely different approach to managing schizophrenia and other psychotic disorders.
We understand that you might not have time to read everything. That's why we're offering a special limited-time deal: subscribe to two newsletters of your choice and get 15% off the regular price!
In this video, we explore the use of alpha-2 agonists in the treatment of ADHD, specifically focusing on guanfacine ER (Intuniv) and clonidine ER (Kapvay). These non-stimulant ADHD medications have become viable options for patients who may not tolerate stimulants or have comorbid conditions that make stimulant medications less effective or problematic.
In this video, Dr. Chris Aiken, Editor-in-Chief of The Carlat Psychiatry Report, provides a comprehensive review of Gepirone, also known as Exxua, a newly FDA-approved antidepressant for major depressive disorder in adults. Gepirone is unique due to its classification as an azipirone, a class of medications that work as serotonin 5-HT1A receptor agonists.
Medication preauthorizations are essential but often frustrating, especially for psychiatric prescriptions. This article offers strategies to reduce revisions, ultimately streamlining the process.
-_-Benefits-Side-Effects-and-Review-of-Trials_Thumb.jpg?height=400&t=1727890706&width=600 "What You Need to Know About Gepirone (Exxua) _ Benefits, Side Effects, and Review of Trials_Thumb.jpg")
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
